AHR American Healthcare REIT, Inc.
American Healthcare REIT, Inc., a Maryland-based self-managed REIT, owns and operates a diversified portfolio of clinical healthcare real estate across the U.S., U.K., and the Isle of Man. Its focus includes senior housing, skilled nursing facilities (SNFs), outpatient medical (OM) buildings, and other healthcare-related properties. The company utilizes a fully integrated management platform and operates senior housing under the RIDEA structure. In addition to owning and operating properties, it has originated and acquired secured loans and may pursue other real estate-related investments opportunistically. The REIT seeks income-generating assets and selectively develops healthcare properties. It has elected to be taxed as a REIT under the U.S. Internal Revenue Code and intends to maintain compliance with REIT requirements. American Healthcare REIT, Inc. is based in Irvine, United States.…
Industry Peers
REIT - Healthcare FacilitiesKey Statistics
About American Healthcare REIT (NYSE: AHR)
›
American Healthcare REIT (NYSE: AHR) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the REIT - Healthcare Facilities industry, part of the Real Estate sector, and reports about 121 employees.
The shares were at 57.55 USD on 20 November 2026, up 18.1% over 52 weeks. Its 52-week range is 44.81 USD to 59.54 USD: the price is 3.4% below the high and 28.4% above the low.
At a market capitalisation of 13.36B USD, it trades at 117.5 times trailing earnings and 64.0 times forward earnings. The median trailing P/E of its 15 largest REIT - Healthcare Facilities peers is 23.1, a premium of 408% for AHR. It pays a dividend yielding 1.74% (it pays out 204% of its earnings), against a median of 5.81% among the dividend payers in that peer group.
American Healthcare REIT reports return on equity of 2.1%, an operating margin of 6.8% and revenue up 29.4% year over year.
Its debt exceeds its cash by 1.30B USD, a debt-to-equity ratio of 0.51. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 16 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 66.69 USD is 15.9% above the current price. The next earnings report is expected on 25 February 2027.